

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2017 June 7; 23(21): 3761-3944



**EDITORIAL**

- 3761 Endoscopic shielding technique, a new method in therapeutic endoscopy

*Bon I, Bartoli R, Lorenzo-Zúñiga V*

- 3765 Role of surgery in pancreatic cancer

*Buanes TA*

**REVIEW**

- 3771 Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!

*Cozma-Petruț A, Loghin F, Miere D, Dumitrașcu DL*

**MINIREVIEWS**

- 3784 New endoscopes and add-on devices to improve colonoscopy performance

*Gkolfakis P, Tziatzios G, Dimitriadis GD, Triantafyllou K*

- 3797 Spontaneous regression of hepatocellular carcinoma: A mini-review

*Sakamaki A, Kamimura K, Abe S, Tsuchiya A, Takamura M, Kawai H, Yamagiwa S, Terai S*

**ORIGINAL ARTICLE****Basic Study**

- 3805 Green tea polyphenols ameliorate non-alcoholic fatty liver disease through upregulating AMPK activation in high fat fed Zucker fatty rats

*Tan Y, Kim J, Cheng J, Ong M, Lao WG, Jin XL, Lin YG, Xiao L, Zhu XQ, Qu XQ*

- 3815 Prevalence of *IFNL3* rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C

*Świątek-Kościelna B, Kaluźna E, Strauss E, Nowak J, Bereszyńska I, Gowin E, Wysocki J, Rembowska J, Barcińska D, Mozer-Lisewska I, Januszkiewicz-Lewandowska D*

- 3825 Corticotropin-releasing factor stimulates colonic motility *via* muscarinic receptors in the rat

*Kim KJ, Kim KB, Yoon SM, Han JH, Chae HB, Park SM, Youn SJ*

- 3832 Clinical significance of changes in the Th17/Treg ratio in autoimmune liver disease

*Feng TT, Zou T, Wang X, Zhao WF, Qin AL*

- 3839 Inhibitory effect of oxymatrine on hepatocyte apoptosis *via* TLR4/PI3K/Akt/GSK-3 $\beta$  signaling pathway

*Zhang X, Jiang W, Zhou AL, Zhao M, Jiang DR*

- 3850 Sodium selenite ameliorates dextran sulfate sodium-induced chronic colitis in mice by decreasing Th1, Th17, and  $\gamma\delta$ T and increasing CD4(+)CD25(+) regulatory T-cell responses

*Sang LX, Chang B, Zhu JF, Yang FL, Li Y, Jiang XF, Wang DN, Lu CL, Sun X*

#### Case Control Study

- 3864 Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients

*Elemeery MN, Badr AN, Mohamed MA, Ghareeb DA*

#### Retrospective Study

- 3876 Relationship between serum adenosine deaminase levels and liver histology in autoimmune hepatitis

*Torgutalp M, Efe C, Babaoglu H, Kav T*

- 3883 Clinical significance of the neutrophil-lymphocyte ratio as an early predictive marker for adverse outcomes in patients with acute pancreatitis

*Jeon TJ, Park JY*

#### Prospective Study

- 3890 Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study

*Keshteli AH, van den Brand FF, Madsen KL, Mandal R, Valcheva R, Kroeker KI, Han B, Bell RC, Cole J, Hoevers T, Wishart DS, Fedorak RN, Dieleman LA*

- 3900 Role of three-dimensional endoanal ultrasound in assessing the anal sphincter morphology of female patients with chronic proctalgia

*Xue YH, Ding SQ, Ding YJ, Pan LQ*

#### Randomized Controlled Trial

- 3907 Pleiotrophin and N-syndecan promote perineural invasion and tumor progression in an orthotopic mouse model of pancreatic cancer

*Yao J, Zhang LL, Huang XM, Li WY, Gao SG*

#### SYSTEMATIC REVIEWS

- 3915 Epidemiology of functional gastrointestinal disorders in children and adolescents: A systematic review

*Boronat AC, Ferreira-Maia AP, Matijasevich A, Wang YP*

#### CASE REPORT

- 3928 Esophageal carcinoma originating in the surface epithelium with immunohistochemically proven esophageal gland duct differentiation: A case report

*Tamura H, Saiki H, Amano T, Yamamoto M, Hayashi S, Ando H, Doi R, Nishida T, Yamamoto K, Adachi S*

- 3934** Ischemic or toxic injury: A challenging diagnosis and treatment of drug-induced stenosis of the sigmoid colon

*Zhang ZM, Lin XC, Ma L, Jin AQ, Lin FC, Liu Z, Liu LM, Zhang C, Zhang N, Huo LJ, Jiang XL, Kang F, Qin HJ, Li QY, Yu HW, Deng H, Zhu MW, Liu ZX, Wan BJ, Yang HY, Liao JH, Luo X, Li YW, Wei WP, Song MM, Zhao Y, Shi XY, Lu ZH*

## ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Spiliotis Manolakopoulos, MD, PhD, Associate Professor, Department of Medicine-Gastroenterology, Athens Medical School, Athens 15343, Greece

## AIMS AND SCOPE

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

## INDEXING/ABSTRACTING

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Directory of Open Access Journals. The 2015 edition of Journal Citation Reports<sup>®</sup> released by Thomson Reuters (ISI) cites the 2015 impact factor for *WJG* as 2.787 (5-year impact factor: 2.848), ranking *WJG* as 38 among 78 journals in gastroenterology and hepatology (quartile in category Q2).

## FLYLEAF

### I-IX Editorial Board

## EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Xiang Li  
Responsible Electronic Editor: Fen-Fen Zhang  
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Ze-Mao Gong  
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL  
*World Journal of Gastroenterology*

ISSN  
ISSN 1007-9327 (print)  
ISSN 2219-2840 (online)

LAUNCH DATE  
October 1, 1995

FREQUENCY  
Weekly

### EDITORS-IN-CHIEF

**Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon**, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

**Stephen C Strom, PhD, Professor**, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

**Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology**, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

### EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

### EDITORIAL OFFICE

Jin-Lei Wang, Director  
Yuan Qi, Vice Director  
Ze-Mao Gong, Vice Director  
*World Journal of Gastroenterology*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

### PUBLISHER

Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpoffice@wjgnet.com](mailto:bpoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE  
June 7, 2017

### COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

### SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

### INSTRUCTIONS TO AUTHORS

Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/2014>

ONLINE SUBMISSION  
<http://www.f6publishing.com>

## Epidemiology of functional gastrointestinal disorders in children and adolescents: A systematic review

Alexandre Canon Boronat, Ana Paula Ferreira-Maia, Alicia Matijasevich, Yuan-Pang Wang

Alexandre Canon Boronat, Ana Paula Ferreira-Maia, Yuan-Pang Wang, Institute & Department of Psychiatry (LIM-23), University of São Paulo Medical School, São Paulo, SP 01060-970, Brazil

Alicia Matijasevich, Department of Preventive Medicine, University of São Paulo Medical School, São Paulo, SP 01246-903, Brazil

**Author contributions:** All authors equally contributed to this paper with regard to conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** No potential conflicts of interest exist.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** Yuan-Pang Wang, MD, PhD, Institute & Department of Psychiatry (LIM-23), University of São Paulo Medical School, R. Dr. Ovidio Pires de Campos, 785, São Paulo, SP 01060-970, Brazil. [gnap\\_inbox@hotmail.com](mailto:gnap_inbox@hotmail.com)  
Telephone: +55-11-26616976  
Fax: +55-11-26616976

Received: January 29, 2017

Peer-review started: February 10, 2017

First decision: March 3, 2017

Revised: March 20, 2017

Accepted: April 12, 2017

Article in press: April 12, 2017

Published online: June 7, 2017

### Abstract

#### AIM

To assess the prevalence of functional gastrointestinal disorders (FGIDs) in children and adolescents.

#### METHODS

PubMed, EMBASE, and Scopus databases were searched for original articles from inception to September 2016. The literature search was made in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. For inclusion, each study had to report epidemiological data on FGIDs in children between 4 and 18 years old and contain standardized outcome based on Rome II, III or IV criteria. The overall quality of included epidemiological studies was evaluated in accordance with Loney's proposal for prevalence studies of health literature. Two reviewers assessed each study for data inclusion and extraction. Discrepancies were reconciled through discussion with seniors.

#### RESULTS

A total of 659 articles were identified from the databases and 16 through manual search. A total of 43 articles fulfilled the eligibility criteria for full-text reading, with 26 remaining to be included in the final analysis. All studies were written in English and published between 2005 and 2016. Eight (30.8%) articles were performed in North America, five (19.2%) in Latin America, five (19.2%) in Europe, seven (27%) in Asia, and one (3.8%) in Africa. Sample size varied between 114 and 99416 subjects, totaling 132600 individuals. Fourteen (53.9%) studies recruited their target samples from schools, 11 (42.3%) from health-care settings and the remaining one (3.8%) from online

panel community. The overall FGID prevalence rates for student samples ranged from 9.9% to 29% to as high as 87% in clinical samples. Cyclic vomiting, irritable bowel syndrome and functional constipation were the most researched conditions, with a prevalence ranging from 0.2% to 6.2%, 0% to 45.1% and 0.5% to 86.9%, respectively. The qualitative appraisal revealed that most of the studies showed average or below average generalizability.

### CONCLUSION

The heterogeneity of the studies on FGIDs must be improved in order to allow comparison. Improvements should include appropriate sampling of representative population, comparable study setting, and consistent data collection.

**Key words:** Functional gastrointestinal disorders; Epidemiology; Prevalence; Children; Adolescents

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Epidemiological studies on functional gastrointestinal disorders in children and adolescents provide variable prevalence rates in both non-clinical and clinical settings. The scarcity of good quality prevalence data for functional gastrointestinal disorders in light of recent Rome IV criteria reveals an urgent need for more trustworthy information to construct evidence-based health policy. The current literature review suggested higher impact of cyclic vomiting, irritable bowel syndrome and functional constipation in children and adolescents.

Boronat AC, Ferreira-Maia AP, Matijasevich A, Wang YP. Epidemiology of functional gastrointestinal disorders in children and adolescents: A systematic review. *World J Gastroenterol* 2017; 23(21): 3915-3927 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i21/3915.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i21.3915>

## INTRODUCTION

Functional gastrointestinal disorders (FGIDs) are considered common, even in children and adolescents. During the last years, the burden of FGIDs is rising<sup>[1-4]</sup>, but no biomarkers<sup>[5]</sup> or gold standard tests are available to date for diagnosing gastrointestinal (GI) disorders without an established etiology<sup>[6]</sup>.

Pediatric guidelines are dynamic over time and must be driven by evidence-based medicine<sup>[7]</sup>. The Rome criteria for FGIDs, currently in its 4<sup>th</sup> edition (Rome IV, May 2016), are guidelines based on a detailed clinical evaluation that must contain complete clinical history, physical examination and growth curves to help clinicians in daily practice<sup>[5,8-10]</sup>.

In the child/adolescent Rome IV chapter, there are

two main changes: (1) the term “no evidence for organic disease” was removed from all definitions and replaced by “after appropriate medical evaluation the symptoms cannot be attributed to another medical condition”; and (2) the FGIDs can co-occur with other medical conditions that themselves result in GI symptoms<sup>[11]</sup>.

Table 1 summarizes main Rome IV categories concerning frequency, duration and synonym, subtypes or approximate terms in three broad sections: (H1) nausea and vomiting disorders; (H2) abdominal pain-related disorders; and (H3) defecation disorders.

Agreed-upon description of GI syndromes and accurate estimates of FGID prevalence are required for defining the need for treatment in overloaded healthcare settings. Projected proportion of pediatric FGID cases in the community and different levels of healthcare setting obtained through epidemiological studies might help to guide proper allocation of financial support and organize health service delivery.

The aim of this literature review was to critically examine current evidence of knowledge on FGIDs in children and adolescents, through systematic search of frequency or prevalence data on common functional GI problems. Furthermore, we have assessed the quality of existing studies on the target topic.

## MATERIALS AND METHODS

### Search strategies

A literature search was conducted in the PubMed, EMBASE, and Scopus databases in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)<sup>[12]</sup>. The search terms were “functional gastrointestinal disorder” OR “functional gastrointestinal symptoms” AND “epidemiology” OR “prevalence” OR “incidence”. In addition, for each of the eleven specific categories of FGIDs in children and adolescents, a new search was performed with the disorder’s nomenclature and equivalent and/or approximate terms. For example, “cyclic vomiting” AND “periodic vomiting” were combined with epidemiological terms (Supplementary Online Content).

There was no language restriction and the period covered was from inception to September 30, 2016. For inclusion, each study had to: (1) contain children and adolescents between 4 and 18 years old; (2) report functional gastrointestinal symptoms and/or disorders according to Rome II, III or IV criteria<sup>[13,14]</sup> (<http://www.romecriteria.org/>); (3) design sample from a birth-cohort, population-based, school-based or clinical setting; and (4) report epidemiological outcomes (prevalence, incidence or frequency) for general FGIDs and subtypes. To complete literature investigation, “similar articles” option, manual search of the reference list on reviewed articles, book chapter, and gray literature were accessed. Experts in pediatric gastroenterology were contacted to request full text or unpublished data. Independently, two

**Table 1** Classification of functional gastrointestinal disorders in children and adolescents

Rome IV nomenclature <sup>1</sup>		Frequency	Duration	Synonym, subtypes or approximate terms
H1: Functional nausea and vomiting disorders				
H1a.	Cyclic vomiting syndrome	≥ 2 periods of intense, unremitting nausea and paroxysmal vomiting	h-d/6 mo	Periodic vomiting
H1b1.	Functional nausea	≥ 2 nausea episodes/wk	≥ 2 mo	Bothersome nausea
H1b2.	Functional vomiting	≥ 1 vomiting episode/wk	≥ 2 mo	-
H1c.	Rumination syndrome	Repetitive regurgitation and rechewing or expulsion of food	≥ 2 mo	Adolescent rumination syndrome <sup>2</sup> ; regurgitation, reswallowing, spitting
H1d.	Aerophagia	Repetitive belching and/or increased flatus	≥ 2 mo	-
H2: Functional abdominal pain disorders				
H2a.	Functional dyspepsia	≥ 1 symptom for ≥ 4 d/mo	≥ 2 mo	Postprandial distress syndrome; Epigastric pain syndrome
H2b.	Irritable bowel syndrome	Abdominal pain for ≥ 4 d/mo	≥ 2 mo	Abdominal discomfort <sup>2</sup> ; Manning criteria
H2c.	Abdominal migraine	≥ 2 intense abdominal pain episodes	≥ 1 h/6 mo	Periumbilical pain <sup>2</sup>
H2d.	Functional abdominal pain - not otherwise specified	≥ 4 episodic or continuous abdominal pain/mo	≥ 2 mo	Functional abdominal pain <sup>2</sup> ; Functional abdominal pain syndrome <sup>2</sup>
H3: Functional defecations disorders				
H3a.	Functional constipation	≤ 2 defecations/wk ≥ 1 fecal incontinence/wk	≥ 1 mo	-
H3b.	Nonretentive fecal incontinence	Episodes of fecal loss	≥ 1 mo	-

<sup>1</sup>After appropriate evaluation, the symptoms cannot be fully explained by another medical condition; <sup>2</sup>Rome III nomenclature.

reviewers (Boronat AC and Ferreira-Maia AP) assessed each study for inclusion and extracted the data. Discrepancies were reconciled through panel discussion with senior authors (Matijasevich A and Wang YP).

### Critical literature appraisal

The overall quality of the studies included was evaluated in accordance with Loney's proposal for prevalence studies in health literature<sup>[15]</sup>. All studies were scored based on eight criteria: (1) sample size; (2) sampling adequacy; (3) unbiased sampling frame; (4) measures of outcomes; (5) unbiased assessors; (6) response rate with refusals described; (7) prevalence with confidence intervals and by relevant subgroups; and (8) appropriate description of study subjects for the research question. One point was attributed for each met criterion. Higher scores indicate better study quality in a scoring range from zero to eight.

The sample size criterion was not used to exclude studies. However, we considered the sample size to be adequate if it was projected for the study on the basis of local population estimates or if it was higher than 370. This minimum sample size was calculated to allow outcome assessment using simple random sampling, with a conservative estimate of 13.9% for distinct FGIDs in the age bracket of children and adolescents<sup>[16]</sup>, confidence level of 95%, and precision of 1.8%, resulting in a minimum sample size of 370 subjects.

Two reviewers (Boronat AC and Ferreira-Maia AP) performed the evaluation and final results were discussed one by one with senior author (Wang YP).

### Methodological issues

For accurate evaluation of the methodological issues

on pediatric epidemiological studies, two questions need be highlighted: (1) how representative of the target population are the recruited participants? (2) are the outcome measures reliable and valid?

### How representative of the target population are the recruited participants?

The most appropriate study design to determine the prevalence of a goal condition (prevalence of FGIDs) is the population-based observational study covering the whole target population, *e.g.*, by census of all subjects between 4-18 years old within a certain area. This is not always possible or feasible as it is a high cost or time-consuming method. Probability sampling, in turn, is essential in prevalence studies to ensure that each potential respondent has an equal chance of selection (non-zero probability), warranting the representativeness of the intended population<sup>[15,17]</sup>.

Convenience sampling provides lower quality epidemiological data than population-based studies. Participants recruited from particular communities (*e.g.*, social network or online panel), schools, primary care and specialty care would result in some types of selection bias. In order to obtain unbiased frequency estimates, all eligible persons susceptible to developing a clinical condition should be included in sampling design, regardless of refusal or reasons of exclusion (*i.e.*, loss to follow-up, incomplete data, and organic exclusion). Otherwise, the rate of disease frequency would be either inflated or reduced.

Assuming that most of children and adolescents are enrolled in schools (except those homeless, correctional institutionalized and hospitalized), conducting a survey in randomly selected schools might be an acceptable alternative. In healthcare treatment settings, the

Berkson's bias may skew the sample characteristics by selecting more symptomatic treatment-seeking individuals.

Sample size is important to ensure measurement precision using confidence limits. Either the confidence interval (CI) or the information needed to calculate CI must be reported to allow quantifying the degree of uncertainty associated with the frequency estimates. Non-representative sampling cannot always be fixed through very large samples. Typically, in case of a high rate of non-response (more than 20%), the socio-demographic characteristics of non-respondent group must be compared with those of respondent group, to evaluate potential selection bias and impact on frequency estimates of target condition<sup>[17]</sup>.

Non-representativeness of recruited participants is a serious threat to external validity by curbing generalization of the results. Hence, effort to fix unequal selection chance is recommended. Weighting procedure and post-stratification adjustment are alternatives to fit the data to target-population structure.

### Are the outcome measures reliable and valid?

The type of informant and the method of data assessment represent potential sources of error for estimating the prevalence rate of clinical conditions. Standardized data collection methods provide reliable and valid measurement of target outcome.

Expert opinions may diverge on the constellation of signs and symptoms of a functional disorder, as well as the frequency and duration of GI ailments. One of the Rome IV's goals is to operationalize the construct of FGIDs through reproducible criteria, since to date there has been no gold standard assessment for it. The validity of categories of FGIDs is still a matter of intense research.

In pediatrics, mainly in younger children samples, it is usual to obtain GI information only through parental report. Studies in older children and adolescents have demonstrated that parent-child/adolescent concordance was largely poor<sup>[18]</sup>. The administration of validated questionnaires like the Questionnaire on Pediatric Gastrointestinal Symptoms (QPGS/QPGS-RIII, parental and/or self-report form)<sup>[17,19]</sup> is a feasible strategy for ascertaining the symptoms of FGIDs, but the establishment of a case based barely on questionnaire responding may mislead to under or over-estimation of problems in children and adolescents. When objective laboratory measure is lacking, as in the case of FGIDs, multisource informants (parent, children or adolescent) and validated questionnaires plus clinical evaluation may constitute the best strategy for the best possible diagnosis, mitigating information bias.

It is recommended that interviewers are impartial to children's health status and trained for identification of cases based on external criteria and decision rules for disease diagnosis (FGIDs)<sup>[15,17]</sup>. Further investigation or therapeutics may confirm or rule out the suspected illness.

Ultimately, the validity and reliability of outcome measures for GI symptoms are intrinsically linked to sensitivity and specificity of the standardized operational procedures, either by independent assessors or assessment tools.

## RESULTS

### Literature search and general description of included studies

The search flow diagram is displayed in Figure 1. A total of 659 articles were identified through the databases and 16 through the manual search. After removing duplicate records, 149 articles remained for title and abstract reading. Of these, 43 articles fulfilled the eligibility criteria for full-text reading. Finally, 26 articles were included in the present review. The 17 studies excluded were listed in the Supplementary Online Content.


All of the articles included ( $n = 26$ ) were written in English and published between 2005 and 2016. Eight studies were performed in North America<sup>[8,18,20-25]</sup>, five in Latin America<sup>[26-30]</sup>, five in Europe<sup>[31-35]</sup>, seven in Asia<sup>[6,16,36-40]</sup>, and one in Africa<sup>[41]</sup>. Five studies were performed by the same Latin American consortium, the Functional International Digestive Epidemiology Research Survey, which adopted a similar methodology, thus allowing comparing the data.

Five articles detailed the distribution of demographic characteristics of the study population. Among the participants, no significant variation for gender<sup>[6,20,26,36]</sup>, age or race<sup>[26]</sup> was observed.

Concerning FGID outcome criterion, the majority of studies ( $n = 18$ ) used Rome III criteria to define each specific GI category<sup>[6,16,23-30,32-35,38-41]</sup>. Five studies used the Rome II criteria to define FGIDs<sup>[19,20-22,37]</sup>, while three others provided comparable data for the versions II and III of Rome criteria<sup>[8,31,36]</sup>. Until the time of review, no study had reported epidemiological data of FGIDs using Rome IV criteria.

In the great majority of eligible articles, the sample was recruited by convenience ( $n = 19$ , 73.1%). Six additional studies described some types of random selection and one study conducted the survey by means of quota sampling. Sample size varied between 114 and 99416 subjects, totaling 132600 individuals. Although most studies ( $n = 19$ ) recruited participants achieving sufficient sample size, the representativeness of FGID epidemiological data from children and adolescent populations constituted a threat to its external validity.

Regardless of recruitment methods, the sampling setting diverged. Fourteen studies recruited target sample from schools, 11 from healthcare settings, and the remaining from an online panel community. As such, the overall FGID prevalence rates for student samples ranged from 9.9% to 29%<sup>[26,41]</sup> to as high as 87% in a specialty gastroenterological care service after organic exclusion<sup>[35]</sup>. This great prevalence variation was reliant on the type of sampling setting.



**Figure 1 Flow diagram of identifying eligible articles<sup>1</sup>.** <sup>1</sup>Flow diagram according to PRISMA ([www.prisma-statement.org](http://www.prisma-statement.org)); <sup>2</sup>Age bracket 4-18 years old; <sup>3</sup>Prevalence only for general FGIDs. FGIDs: Functional gastrointestinal disorders.

Seven school-based studies included multiple schools without randomization<sup>[6,26-30,34]</sup>. Among health-care settings, most of studies ( $n = 8$ ) recruited participants from a single tertiary care center<sup>[8,19-24,31,33]</sup>, two from secondary care<sup>[32,35]</sup>, and the remaining one from primary care<sup>[22]</sup>. As such, the proportion of FGIDs in treated patient samples was much higher than school-based student samples.

Specific categories of FGIDs in half of the articles ( $n = 13$ ) were exclusively informed by questionnaire, either parental report and/or self-report by children and adolescents<sup>[23,25-30,34,36,38-41]</sup>, while the other half ( $n = 13$ ) also included clinical evaluation and/or medical records<sup>[6,8,16,19,20-22,24,31-33,35,37]</sup>.

Of interest, the agreement rate between dyads of informants (parents and children) and informant-physician varied greatly in magnitude<sup>[19,21,24]</sup>, within the groups of FGIDs. This non-agreement rate, as expressed through the kappa coefficient, is a serious issue to the prevalence data, as follows.

**Functional nausea and vomiting disorders (H1):** the parent-children agreement for cyclic vomit was moderate ( $k = 0.42$ )<sup>[19]</sup>, and that for aerophagia ranged from no to substantial agreement<sup>[19,24]</sup>.

**Functional abdominal pain disorders (H2):** the parent-children agreement for dyspepsia was fair to substantial<sup>[19,21,24]</sup>, but this concordance could not replicate for informant-physician dyads (kappa range: 0.02 to -0.06)<sup>[24]</sup>. Considerable disagreements across all dyads were reported for the irritable bowel syndrome (IBS; kappa range: 0.03 to 0.44) and functional abdominal pain (kappa range: -0.10 to

-0.02)<sup>[24]</sup>. Likewise, the agreement for abdominal migraine ranged from poor to moderate in the parent-children dyad<sup>[18,24]</sup>.

**Functional defecation disorders (H3):** while the agreement rate for constipation was fair across all dyads<sup>[24]</sup>, no evidence of agreement was reported for fecal retention and nonretentive fecal soiling<sup>[19]</sup>.

Because there is no reliable concordance between dyads, the quality and the magnitude of prevalence data of FGIDs in children and adolescents can be distorted by the type of informant. The observed rate of 7.7% for any FGID among German children cannot be trusted, since the data were solely based on parent report<sup>[34]</sup>.

In terms of outcome criteria, the agreement between Rome II and Rome III to diagnose FGIDs was poor ( $k = 0.114$ )<sup>[31]</sup>. Under more sensitive Rome III criteria, the reported prevalence of FGID might at least double relative to Rome II<sup>[8,36]</sup>. Since there are no published data based on Rome IV criteria, the effect of this new version on FGID prevalence could not be compared.

The appraisal of the 26 included studies indicated that good quality studies reporting the epidemiology of main categories of FGIDs in children and adolescents were scarce, likewise recent reviews of FGIDs in infants and toddlers<sup>[42,43]</sup>.

According to Loney's proposal<sup>[15]</sup>, a higher score of six was achieved by three school-based studies conducted in Japan<sup>[16,40]</sup> and China<sup>[37]</sup>. In general, the studies presented poor quality in half of the retained articles ( $n = 13$ ), scoring 2 or a maximum of 3 points. By far, the most common problem was prevalence

rates without confidence interval and/or no detailed information on subgroup ( $n = 21$ ), inappropriate sampling frame ( $n = 21$ ), inadequate sampling method ( $n = 19$ ), no description of refusers ( $n = 14$ ) and/or insufficient sample size ( $n = 7$ ) (Table S1).

Regarding the main epidemiological results on FGIDs, we describe sequentially the groups of H1 (vomiting and aerophagia) in Table 2, H2 (abdominal pain-related functional GI disorders) in Table 3, and H3 (constipation and incontinence) in Table 4. Among the single categories of FGIDs, cyclic vomiting, IBS and constipation were the most researched conditions.

### **Vomiting and aerophagia**

There were 12 studies reporting frequency data on vomiting and aerophagia in children and adolescents (Table 2). The choice of the QPGS or parental report to assess the FGID symptoms was the rule. Seven studies were school-based surveys<sup>[6,16,26-28,30,36]</sup>. Six studies also included external clinical assessment and/or medical records<sup>[6,16,19,22,24,35]</sup>. For the remaining ones, nine studies used information self-reported by the children or adolescents, while nine used parental report, and six used both types of forms.

Cyclic vomiting and aerophagia were uncommon FGIDs in this age group, although they were the most frequent data collected on the group H1. There were dissimilar rates reported across studies, ranging from 0.2% to 6.2%<sup>[6,19]</sup> and 0% to 15%<sup>[24,35]</sup>, respectively, for cyclic vomiting and aerophagia. The investigation setting, namely, school-based or healthcare centers, can be considered as influencing factors.

Information on rumination was less reported; the rates ranged from 0.3% to 5.3% in nine studies. There were no available data for functional nausea and functional vomiting since these are new categories proposed in the Rome IV criteria.

### **Abdominal pain-related functional GI disorders**

Twenty-three studies addressed this FGID group (H2; Table 3), with IBS being the most reported category across eligible studies. Two large sample studies in China ( $n = 3671$  and  $5403$ ) dedicated to explore the prevalence of IBS in school-based settings<sup>[37,38]</sup>. Data on dyspepsia, abdominal migraine and abdominal pain-not otherwise specified (NOS) were reported in 21 studies. Similarly to the H1 group, QPGS was also the standard assessment tool for reporting the symptoms of abdominal pain-related disorders. School and healthcare setting were the major sources of participant recruitment.

Given its disabling feature, there was a major interest to understand the occurrence and clinical characteristic of IBS. Across all studies on children and adolescents, the rates of IBS ranged from 0% to 45.1%<sup>[8,22]</sup> according to the setting of recruitment. Possibly, the prevalence rate of IBS would be lower in schools and inflated in healthcare settings due to its

disabling condition.

Similarly, the wide prevalence variations of other categories of abdominal pain resulted from the representative sample selection. For instance, the prevalence rate for dyspepsia ranged from 0.2% to 25.7%<sup>[25,33,34]</sup>, abdominal migraine 0% to 23.1%<sup>[8,33]</sup>, and abdominal pain-NOS 0.3% to 39.8%<sup>[26,28,33]</sup>. Of note, the prevalence rates of the H2 group were much higher than those of the H1 group, suggesting frequent help-seeking behavior and greater burden.

### **Defecation problems**

Table 4 shows 14 epidemiological studies on defecation problems in children and adolescents (H3 group). Twelve studies used self-report form for children and adolescents or parent report with QPGS form, and six studies also included some types of clinical evaluation (physical examination, laboratory examinations, or medical records). Most investigations ( $n = 9$ ) conducted the study in schools.

Constipation was investigated in all 14 studies and discrepant rates of prevalence ranged from 0.5% to 86.9%<sup>[6,31]</sup>. School-based studies reported the lowest prevalence and the tertiary care the highest rate. In comparison with the Rome II criteria, the use of broader Rome III also expanded the prevalence rate<sup>[31]</sup>.

Nonretentive fecal incontinence seemed to be a rare disorder, with a prevalence rate ranging from 0% to 1.8%<sup>[25,28]</sup> in all retained studies ( $n = 10$ ). Even in non-health settings, a low prevalence of GI disorder was observed, requiring further careful assessment in more representative samples.

## **DISCUSSION**

This study is a systematic review on the epidemiology of FGIDs in children and adolescents. From a total number of 675 identified articles addressing the issue, 26 were included in the final analysis (around 132600 subjects). Search strategies, methodological issues and critical appraisal of literature were systematically presented to summarize the prevalence data on FGIDs in the pediatric population. Cyclic vomiting, IBS and constipation were the most researched conditions, with prevalence ranging from 0.2% to 6.2%, 0% to 45.1% and 0.5% to 86.9%, respectively. This wide variation in prevalence hampers the comparability of epidemiological data, whose reliability needs improvements. The qualitative appraisal revealed that most of the studies showed average or below average generalizability. Several limitations of eligible studies have been acknowledged concerning, *e.g.*, correct sampling of representative population, study setting, and data collection. Future directions in the field of epidemiological studies concerning pediatric FGIDs must follow a more correct methodology, such as appropriate sampling of representative population, comparable study setting, and consistent collection

Table 2 Prevalence or frequency of functional gastrointestinal disorders: Nausea and vomiting problems in children and adolescents

Author, year, country	Study design, setting	Sample size (participation %)	Age bracket yr	Case definition	Case ascertainment	Score <sup>1</sup>	FGID subtype prevalence % (CI 95%)		
							Cyclic vomiting	Aerophagia	Rumination
Bhatia <i>et al</i> <sup>[6]</sup> , 2016, India	Cross-sectional, school-based	1200 (93.3)	10-17	Rome III	Self-reported QPGS-RIII Medical records	5	0.2	1.5	0.3
Caplan <i>et al</i> <sup>[18]</sup> , 2005, Canada	Cross-sectional, tertiary care	315 (NIR)	4-18	Rome II	Self-reported QPGS Parental QPGS Clinical evaluation	3	p 4-9 yr = 6.2 p 10-18 yr = 2.2 a 10-18 yr = 4.3	p 4-9 yr = 1.1 p 10-18 yr = 2.2 a 10-18 yr = 1.4	
Devanarayana <i>et al</i> <sup>[60]</sup> , 2010, Sri Lanka	Cross-sectional, school-based	464 (92)	12-16	Rome II	Self-reported QPGS	4	0.2	6.1	
Helgeland <i>et al</i> <sup>[35]</sup> , 2009, Norway	Cross-sectional, secondary care	192 (79.1)	4-15	Rome III Rome III	Parental QPGS-RIII Clinical evaluation Medical records	3	0.5 6.0	6.3 15.0	4.0 2.0
Játiva <i>et al</i> <sup>[50]</sup> , 2016, Ecuador	Cross-sectional, school-based	420 (99.3)	8-15	Rome III	Self-reported QPGS-RIII Parental standard questionnaire	3	1.0	2.6	0.7
Lewis <i>et al</i> <sup>[25]</sup> , 2016, United States	Cross-sectional, online panel community	1447 (NIR)	4-18	Rome III	Parental QPGS-RIII PedsQL4.0	2	1.1	4.3	0.0
Lu <i>et al</i> <sup>[28]</sup> , 2016, Panama	Cross-sectional, school-based	436 (82.8)	8-14	Rome III	Self-reported QPGS-RIII Parental standard questionnaire	4	0.3 (0.0-0.9)	0.3 (0.0-0.9)	0.0
Sagawa <i>et al</i> <sup>[16]</sup> , 2012, Japan	Cross-sectional, school-based	3976 (NIR)	10-17	Rome III	Self-reported QPGS-RIII Self-reported PedsQL4.0	6	0.2	2.0	0.1
Saps <i>et al</i> <sup>[26]</sup> , 2014, Colombia	Cross-sectional, school-based	488 (83.2)	10.0 (mean age)	Rome III	Self-reported QPGS-RIII Clinical evaluation Parental standard questionnaire	4	0.3 (0.0-1.7)		
Uc <i>et al</i> <sup>[22]</sup> , 2006, United States	Cross-sectional, primary care	243 (100)	4-17	Rome II	Parental QPGS Clinical evaluation	4	0.8	2.5	
van Tilburg <i>et al</i> <sup>[24]</sup> , 2013, United States	Cross-sectional, tertiary care	135 (NIR)	4-18	Rome III	Self-reported QPGS-RIII Parental QPGS-RIII Clinical evaluation Medical records	3	p = 0.8 c/a = 5.3 ph = 0	p = 0.8 c/a = 3.5 ph = 0	p = 0.8 c/a = 5.3 ph = 0
Zablah <i>et al</i> <sup>[27]</sup> , 2015, El Salvador	Cross-sectional, school-based	434 (NIR)	8-15	Rome III	Self-reported QPGS-RIII Parental standard questionnaire	3		0.5	0.2

<sup>1</sup>Score: Methodological strength of study (maximum 8) by Loney's criteria. NIR: Not reported; w: With; p: Parents; c: Children; a: Adolescents; ph: Physician; QPGS-RIII: Questionnaire on Pediatric Gastrointestinal Symptoms - Rome III; QPGS: Questionnaire on Pediatric Gastrointestinal Symptoms - Rome II; PedsQL4.0 Pediatric Quality of Life version Inventory 4.0.

Table 3 Prevalence or frequency of functional gastrointestinal disorders: Abdominal pain problems in children and adolescents

Author, year, country	Study design, setting	Sample size (participation %)	Age bracket yr	Case definition	Case ascertainment	Score <sup>1</sup>	Dyspepsia	FGID subtype prevalence % (95%CI)	Abdominal migraine	Abdominal pain - NOS
Baber <i>et al</i> <sup>[8]</sup> , 2008, United States	Cross-sectional, tertiary care	548 (80.1)	8-17	Rome II	Parental QPGS	5	19.6	44.0	5.7	2.7
				Rome III	Clinical evaluation Medical records		15.2	45.1	23.1	17.4
Bhatia <i>et al</i> <sup>[6]</sup> , 2016, India	Cross-sectional, school-based	1200 (93.3)	10-17	Rome III	Laboratory exams Self-reported QPGS-RIII Medical records	5	2.7	1.3	1.4	0.8
Caplan <i>et al</i> <sup>[8]</sup> , 2005, Canada	Cross-sectional, tertiary care	315 (NR)	4-18	Rome II	Physical examination Self-reported QPGS	3	p 4-9 yr = 13.5 p 10-18 yr = 14.4	p 4-9 yr = 22.0 p 10-18 yr = 23.9	p 4-9 yr = 0 p 10-18 yr = 0.7	p 4-9 yr = 0 p 10-18 yr = 2.9
				Rome III	Parental QPGS Clinical evaluation	4	a 10-18 yr = 10.2 25.7	a 10-18 yr = 35.5 34.5	a 10-18 yr = 2.2 0.0	a 10-18 yr = 2.9 39.8
Cristofori <i>et al</i> <sup>[33]</sup> , 2014, Italy	Cross-sectional, tertiary care	992 (NR)	4-16	Rome III	Clinical evaluation Medical records	4				
Devanarayana <i>et al</i> <sup>[60]</sup> , 2010, Sri Lanka	Cross-sectional, school-based	464 (92)	12-16	Rome II	Laboratory exams Self-reported QPGS	4	1.2	2.8	0.2	1.4
				Rome III			3.5	7.0	0.2	3.0
Dong <i>et al</i> <sup>[67]</sup> , 2005, China	Cross-sectional, school-based	5403 (NR)	6-18	Rome II	Self-reported standard questionnaire	6		13.2		
Gijbbers <i>et al</i> <sup>[23]</sup> , 2014, the Netherlands	Cross-sectional, secondary care	220 (NR)	4-16	Rome III	Parental standard questionnaire Medical records	3	3.6	5.0	0.0	15.0
				Rome III	Clinical evaluation Medical records					
Gulewitsch <i>et al</i> <sup>[34]</sup> , 2013, Germany	Cross-sectional, school-based	3658 (43.1)	5-12	Rome III	Laboratory exams Parental QPGS-RIII Parental CSI	2	0.2	4.9	1.0	3.6
				Rome III	Parental SDQ Parental QPGS-III	3	10.0	43.0	23.0	15.0
Helgeland <i>et al</i> <sup>[35]</sup> , 2009, Norway	Cross-sectional, secondary care	192 (NR)	4-15	Rome III	Clinical evaluation Medical records Physical examination					
Játiva <i>et al</i> <sup>[30]</sup> , 2016, Ecuador	Cross-sectional, school-based	420 (99.3)	8-15	Rome III	Laboratory exams Self-reported QPGS-RIII Parental standard questionnaire	3	0.5	4.8	2.4	3.1
				Rome III	PedsQL4.0	2	0.2	2.8	9.2	11.6
Lewis <i>et al</i> <sup>[25]</sup> , 2016, United States	Cross-sectional, online painel community	1447 (NR)	4-18	Rome III	Self-reported QPGS-RIII Parental standard questionnaire	3		4.8		
Lu <i>et al</i> <sup>[20]</sup> , 2016, Colombia	Cross-sectional, school-based	4751 (89.8)	8-18	Rome III	Self-reported QPGS-RIII Parental standard questionnaire	4	0.9 (0.0-2.0)	5.6 (3.1-8.1)	1.7 (0.2-2.9)	3.7 (1.7-5.8) 0.3 (0.0-0.9)
Lu <i>et al</i> <sup>[28]</sup> , 2016, Panama	Cross-sectional, school-based	436 (82.8)	8-14	Rome III	Self-reported QPGS-RIII Parental standard questionnaire					

Sagawa <i>et al.</i> <sup>[16]</sup> , 2012, Japan	Cross-sectional, school-based	3976 (NR)	10-17	Rome III	Self-reported QPGS-RIII Self-reported PedsQL4.0 Clinical evaluation	6	0.9	5.9	1.8	4.2
Saps <i>et al.</i> <sup>[21]</sup> , 2012, United States	Cross-sectional, Community	984 (25)	4-18	Rome III	Parental QPGS-III	2				8.1
Saps <i>et al.</i> <sup>[26]</sup> , 2014, Colombia	Cross-sectional, school-based	488 (83.2)	10.0 (mean age)	Rome III	Self-reported QPGS-RIII Parental standard questionnaire	4	1.7 (0.8-3.9)	5.4 (3.9-8.8)	1.0 (0.3-2.8)	2.7 (1.6-5.2) 0.3 (0.0-1.7)
Schurman <i>et al.</i> <sup>[21]</sup> , 2005, United States	Cross-sectional, tertiary care	205 (75)	8-18	Rome II	Self-reported QPGS Clinical evaluation	3	p = 47 c/a = 35 ph = 57	p = 20; c/a = 30; ph = 12	p < 10 c/a < 10; ph < 10	p < 10 c/a < 10 ph < 10
Uc <i>et al.</i> <sup>[22]</sup> , 2006, United States	Cross-sectional, primary care	243 (100)	4-17	Rome II	Parental QPGS Clinical evaluation	4	0.8	0.0	0.4	0.4
Udoh <i>et al.</i> <sup>[61]</sup> , 2016, Nigeria	Cross-sectional, school-based	856 (NR)	10-18	Rome III	Self-reported QPGS-RIII Standard questionnaires	4	0.4	5.6	1.8	2.6
Walker <i>et al.</i> <sup>[20]</sup> , 2004, United States	Cross-sectional, tertiary care	114 (NR)	4-17	Rome II	Parental QPGS Clinical evaluation	3	15.9	44.9	4.7	7.5
Yanamoto <i>et al.</i> <sup>[40]</sup> , 2015, Japan	Cross-sectional, school-based	99416 (92.2)	12-18	Rome III	Medical records Physical examination Laboratory exams Self-reported standard questionnaire	6		18.6 (17.9-19.2)		
Zablah <i>et al.</i> <sup>[27]</sup> , 2015, El Salvador	Cross-sectional, school-based	434 (NR)	8-15	Rome III	Self-reported QPGS-RIII Parental standard questionnaire	3	1.7	3.7	0.7	3.0
Zhou <i>et al.</i> <sup>[38]</sup> , 2011, China	Cross-sectional, school-based	3671 (NR)	12-18	Rome III	Self-reported standard questionnaire	5		19.8 (18.6-21.1)		

<sup>1</sup>Score: Methodological strength of study (maximum 8) by Loney's criteria; NR: Not reported; w: With; p: Parents; c: Children; a: Adolescents; ph: Physician; QPGS-RIII: Questionnaire on Pediatric Gastrointestinal Symptoms - Rome III; QPGS: Questionnaire on Pediatric Gastrointestinal Symptoms - Rome II; PedsQL4.0 Pediatric Quality of Life version Inventory 4.0CSI: Children's Somatization Inventory; SDQ: Strengths and Difficulties Questionnaire.

of functional GI symptoms. The scarcity of good quality prevalence data for FGIDs in light of recent Rome IV criteria reveals an urgent need for more trustworthy information to construct evidence-based health policy.

To the best of our knowledge, comprehensive review of prevalence of FGIDs in the age bracket of children and adolescents as a group is lacking. Since the prevalence of a disease can cater for decisions and investments on health policies, good quality epidemiological data are required to understand the neurobiology of the brain-gut axis neurobiology in FGIDs, in view of pursuing applicable treatments in pediatrics.

After reviewing eligible papers on FGIDs, the problem of sample selection must be regarded as the foremost concern. The large variation of the prevalence rates can be attributable to lack of representative children and adolescent sample population. The fact that most of studies in the present review recruited their participants by convenience increases the chance to assess a biased sample with some specific characteristics, mostly in particular schools, chosen by suitability<sup>[28,30]</sup> or specialized treatment centers<sup>[33,35]</sup>. Ideally, some types of randomization should be included before the sample recruitment. Clustered and stratified samplings are alternative approaches when a complete list of population is not available<sup>[16,37,40,41]</sup>. The more the sample resembles the general population, the better is the quality data.

The type of setting also contributes to skewing the sample selection. In the case of children and adolescents aged between 4 and 18 years, school-based sample is a reasonable approach in epidemiological surveys, provided that most of the population in that age bracket are enrolled in a school. Conversely, hospitalized, institutionalized,

**Table 4 Prevalence or frequency of functional gastrointestinal disorders: Defecations problems in children and adolescents**

Author, year, country	Study design, setting	Sample size (participation %)	Age bracket yr	Case definition	Case ascertainment	Score <sup>1</sup>	FGID subtype prevalence % (95%CI)	
							Constipation	Nonretentive fecal incontinence
Bhatia <i>et al</i> <sup>[6]</sup> , 2016, India	Cross-sectional, school-based	1200 (93.3)	10-17	Rome III	Self-reported QPGS-RIII Medical records Physical examination	5	0.5	0.4
Burgers <i>et al</i> <sup>[31]</sup> , 2012, Netherlands	Cross-sectional (retrospective), tertiary care	176 (NR)	6-18	Rome II	Clinical evaluation	3	5.7	
				Rome III	Medical records Physical examination		86.9	
Caplan <i>et al</i> <sup>[18]</sup> , 2005, Canada	Cross-sectional, tertiary care	315 (NR)	4-18	Rome II	Self-reported QPGS	3	p 4-9 yr = 19.2	p 4-9 yr = 0.6
					Parental QPGS		p 10-18 yr = 13.8	p 10-18 yr = 0.7
					Clinical evaluation		c/a 10-18 yr = 15.2	c/a 10-18 yr = 0.7
Devanarayana <i>et al</i> <sup>[36]</sup> , 2010, Sri Lanka	Cross-sectional, school-based	464 (92)	12-16	Rome II	Self-reported QPGS	4	1.4	0.2
Helgeland <i>et al</i> <sup>[35]</sup> , 2009, Norway	Cross-sectional, tertiary care	192 (NR)	4-15	Rome III	Parental QPGS-III	3	4.2	0.2
					Clinical evaluation		6.0	
					Medical records Physical examination Laboratory exams			
Játiva <i>et al</i> <sup>[30]</sup> , 2016, Ecuador	Cross-sectional, school-based	420 (99.3)	8-15	Rome III	Self-reported QPGS-RIII Parental standard questionnaire	3	11.8	0.2
Lewis <i>et al</i> <sup>[25]</sup> , 2016, United States	Cross-sectional, online painel community	1447 (NR)	4-18	Rome III	Parental QPGS-RIII PedsQL4.0	2	12.9	1.8
Lu <i>et al</i> <sup>[29]</sup> , 2016, Colombia	Cross-sectional, school-based	4751 (89.8)	8-18	Rome III	Self-reported QPGS-RIII	3	12.7	
					Parental standard questionnaire			
Lu <i>et al</i> <sup>[28]</sup> , 2016, Panama	Cross-sectional, school-based	436 (82.8)	8-14	Rome III	Rome III	4	15.9 (11.9-19.9)	0 (0.0-0.0)
					Self-reported QPGS-RIII Parental standard questionnaire			
Rajindrajith <i>et al</i> <sup>[39]</sup> , 2013, Sri Lanka	Cross-sectional, school-based	1855 (96.7)	13-18	Rome III	Self-reported QPGS-RIII Self-reported PedsQL4.0	5	7.7	
Sagawa <i>et al</i> <sup>[16]</sup> , 2012, Japan	Cross-sectional, school-based	3976 (NR)	10-17	Rome III	Rome III	6	0.3	0.2
					Self-reported QPGS-RIII			
					Self-reported PedsQL4.0 Clinical evaluation			
Saps <i>et al</i> <sup>[26]</sup> , 2014, Colombia	Cross-sectional, school-based	488 (83.2)	10.0 (mean age)	Rome III	Self-reported QPGS-RIII Parental standard questionnaire	4	14.0 (12.0-19.3)	1.5 (0.7-3.6)
Uc <i>et al</i> <sup>[22]</sup> , 2006, United States	Cross-sectional, primary care	243 (100)	4-17	Rome II	Parental QPGS Clinical evaluation	4	16.1	0.4

Zablah <i>et al</i> <sup>[27]</sup> , 2015, El Salvador	Cross-sectional, school-based	434 (NR)	8-15	Rome III	Self-reported QPGS-RIII Parental standard questionnaire	3	10.0	0.0
Zhou <i>et al</i> <sup>[38]</sup> , 2011, China	Cross-sectional, school-based	3671 (NR)	12-18	Rome III	Self-reported standard questionnaire	5	24.9 (23.5-26.3)	

<sup>1</sup>Score: Methodological strength of study (maximum 8) by Loney's criteria. NR: Not reported; w: With; p: Parents; c: Children; a: Adolescents; ph: Physician; QPGS-RIII: Questionnaire on Pediatric Gastrointestinal Symptoms - Rome III; QPGS: Questionnaire on Pediatric Gastrointestinal Symptoms - Rome II; PedsQL4.0 Pediatric Quality of Life version Inventory 4.0.

and homeless populations are not included. On the other hand, only a minor part of the population can be represented in samples drawn from treatment centers, which may exhibit high tendency to help-seeking behavior. Patient samples incur in a double problem, as far as parents interfere with the decision of medical encounter and more symptomatic individuals are recruited into the study. The very large variation reported in the prevalence rates across all retained studies suggests imprecise estimates: while school-based studies may exemplify the closer magnitude of FGID rate<sup>[16,40]</sup>, healthcare centers used to provide inflated rates<sup>[8,33,35]</sup>.

Rome criteria are based on detailed clinical evaluation<sup>[5,8-10]</sup>. To date, no biomarkers<sup>[5]</sup> or standard tests are available to diagnose functional disorders<sup>[6]</sup>. Still, some studies in this review approached the sample only by questionnaires, without clinical assessment<sup>[22,27,28,30,36]</sup>. The lack of medical evaluation can misdiagnose the complaint of FGID symptoms, leading to non-agreement between informants<sup>[19,21,24]</sup>. Some evidence of parent-children concordance was described for cyclic vomit, abdominal migraine and constipation. When a high level of disagreement occurs, *e.g.*, IBS and dyspepsia, the type of informant is critical to the quality of the data. Therefore, wider dissemination of clear operationalized criteria, as in the Rome IV criteria, should be recommended for researchers and practicing pediatricians<sup>[44]</sup>.

### Limitation

Taking all appraisals into account, conclusive recommendation on the results of the epidemiology of FGIDs should be avoided. There are enormous rate differences and unequivocal methodological limitations across studies. Bearing this in mind, some limitations of the current review need to be discussed. Reporting bias in cross-sectional data is commonly due to publication delay (file drawer bias) and language bias. After trying to contact experts to request non-published data (*e.g.*, non-accessible journals, poster presentation, conference paper) and surveys in other language, we were not able to get access to four studies identified in the initial search. Therefore, it is reasonable to assert that the prevalence heterogeneity of the present review is more attributable to the quality

caveats of accessible investigations than to publication bias.

## ACKNOWLEDGMENTS

The authors thank Graziela Risolia Gallo for proofreading the original manuscript.

## COMMENTS

### Background

Functional gastrointestinal disorders (FGIDs) in children and adolescents are mainly a clinical condition and the most common diagnosis in gastroenterology, with a risen burden and, until now, without biomarkers or gold standard diagnosing test available. Furthermore, etiology remains non-established and valid epidemiological data are scarce. The aim of this review was to examine current evidence of knowledge on FGIDs in children and adolescents, through systematic search of frequency or prevalence data on common functional GI problems. The authors also assessed the quality of existing studies on the target topic.

### Research frontiers

The validity of explicit diagnostic criteria and the reliability of psychometric tools for FGIDs are still limited. Pediatricians must rely on patient's symptoms to diagnose and be aware that there are differences between patient and parents reports. Adequate adoption of structured guidelines is useful when replicability is necessary. Reliable data from prospective studies based on structured criteria is necessary to achieve more accurate prevalence data on GI symptoms. Hence, public health decisions can only be established after well-conducted surveys.

### Innovations and breakthroughs

FGIDs in children and adolescents seem to be common in clinical and non-clinical settings, mainly cyclic vomiting, irritable bowel syndrome and functional constipation. Conversely, few good quality population-based studies on epidemiology have been conducted so far and good quality epidemiological data to support diagnostic criteria are lacking. As an effort to optimize FGID identification, the use of Rome criteria proved to be a helpful tool. A Rome criteria update, recently launched as Rome IV, merges scientific features and clinical practice, improving the diagnostic classification system. Therefore, its incorporation into epidemiological surveys and clinical practice may increase the pathophysiological comprehension of GI conditions, leading to diagnostic improvement of an important group of functional diseases with a growing burden in the pediatric and adolescent population.

### Applications

This review highlights future directions for research: (1) epidemiological, well-designed (sample recruitment, representativeness and clinical assessment) and structured (reproducible) studies shall be conducted among all pediatric levels; (2) classification system on FGIDs must be simple and easy to comprehend, looking for a wider use among pediatricians; and (3) multidimensional approach may bring advances for the Rome criteria symptom-based classification.

## Terminology

FGIDs comprise chronic or recurrent symptoms that arise in the absence of anatomic abnormality, inflammation, or tissue damage. The symptoms are variable among children and adolescents.

## Peer-review

This systematic review has been presenting a well-designed study on the epidemiology of FGIDs in children and adolescents. Based on the whole data the authors indicate the need for methodology improvement in future epidemiological studies concerning FGIDs.

## REFERENCES

- 1 **Dhroove G**, Chogle A, Saps M. A million-dollar work-up for abdominal pain: is it worth it? *J Pediatr Gastroenterol Nutr* 2010; **51**: 579-583 [PMID: 20706149 DOI: 10.1097/MPG.0b013e3181de0639]
- 2 **Hoekman DR**, Rutten JM, Vlieger AM, Benninga MA, Dijkgraaf MG. Annual Costs of Care for Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, and Functional Abdominal Pain Syndrome. *J Pediatr* 2015; **167**: 1103-1108.e2 [PMID: 26329806 DOI: 10.1016/j.jpeds.2015.07.058]
- 3 **Park R**, Mikami S, LeClair J, Bollom A, Lembo C, Sethi S, Lembo A, Jones M, Cheng V, Friedlander E, Nurko S. Inpatient burden of childhood functional GI disorders in the USA: an analysis of national trends in the USA from 1997 to 2009. *Neurogastroenterol Motil* 2015; **27**: 684-692 [PMID: 25809794 DOI: 10.1111/nmo.12542]
- 4 **Sommers T**, Corban C, Sengupta N, Jones M, Cheng V, Bollom A, Nurko S, Kelley J, Lembo A. Emergency department burden of constipation in the United States from 2006 to 2011. *Am J Gastroenterol* 2015; **110**: 572-579 [PMID: 25803399 DOI: 10.1038/ajg.2015.64]
- 5 **Jung HK**. Rome III Criteria for Functional Gastrointestinal Disorders: Is There a Need for a Better Definition? *J Neurogastroenterol Motil* 2011; **17**: 211-212 [PMID: 21860813 DOI: 10.5056/jnm.2011.17.3.211]
- 6 **Bhatia V**, Deswal S, Seth S, Kapoor A, Sibal A, Gopalan S. Prevalence of functional gastrointestinal disorders among adolescents in Delhi based on Rome III criteria: A school-based survey. *Indian J Gastroenterol* 2016; **35**: 294-298 [PMID: 27554498 DOI: 10.1007/s12664-016-0680-x]
- 7 **Jacobson RM**. Pediatrics and evidence-based medicine revisited. *J Pediatr* 2007; **150**: 325-326 [PMID: 17382101 DOI: 10.1016/j.jpeds.2006.12.044]
- 8 **Baber KF**, Anderson J, Puzanovova M, Walker LS. Rome II versus Rome III classification of functional gastrointestinal disorders in pediatric chronic abdominal pain. *J Pediatr Gastroenterol Nutr* 2008; **47**: 299-302 [PMID: 18728525 DOI: 10.1097/MPG.0b013e31816c4372]
- 9 **Mostafa R**. Rome III: The functional gastrointestinal disorders, third edition, 2006. *World J Gastroenterol* 2008; **14**: 2124-2125 [DOI: 10.3748/wjg.14.2124]
- 10 **Drossman DA**. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology* 2006; **130**: 1377-1390 [PMID: 16678553 DOI: 10.1053/j.gastro.2016.02.032]
- 11 **Hyams JS**, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional Disorders: Children and Adolescents. *Gastroenterology* 2016; Epub ahead of print [PMID: 27144632 DOI: 10.1053/j.gastro.2016.02.015]
- 12 **Moher D**, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**: e1000097 [PMID: 19621072 DOI: 10.1371/journal.pmed.1000097]
- 13 **Rasquin-Weber A**, Hyman PE, Cucchiara S, Fleisher DR, Hyams JS, Milla PJ, Staiano A. Childhood functional gastrointestinal disorders. *Gut* 1999; **45** Suppl 2: II60-II68 [PMID: 10457047 DOI: 10.1136/gut.45.2008.ii60]
- 14 **Rasquin A**, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, Walker LS. Childhood functional gastrointestinal disorders: child/adolescent. *Gastroenterology* 2006; **130**: 1527-1537 [PMID: 16678566 DOI: 10.1053/j.gastro.2005.08.063]
- 15 **Loney PL**, Chambers LW, Bennett KJ, Roberts JG, Stratford PW. Critical appraisal of the health research literature: prevalence or incidence of a health problem. *Chronic Dis Can* 1998; **19**: 170-176 [PMID: 10029513]
- 16 **Sagawa T**, Okamura S, Kakizaki S, Zhang Y, Morita K, Mori M. Functional gastrointestinal disorders in adolescents and quality of school life. *J Gastroenterol Hepatol* 2013; **28**: 285-290 [PMID: 22988951 DOI: 10.1111/j.1440-1746.2012.07257.x]
- 17 **Boyle MH**. Guidelines for evaluating prevalence studies. *Evid Based Ment Health* 1998; **1**: 37-39 [DOI: 10.1136/ebmh.1.2.37]
- 18 **Caplan A**, Walker L, Rasquin A. Development and preliminary validation of the questionnaire on pediatric gastrointestinal symptoms to assess functional gastrointestinal disorders in children and adolescents. *J Pediatr Gastroenterol Nutr* 2005; **41**: 296-304 [PMID: 16131984 DOI: 10.1097/01.mpg.0000172748.64103.33]
- 19 **Caplan A**, Walker L, Rasquin A. Validation of the pediatric Rome II criteria for functional gastrointestinal disorders using the questionnaire on pediatric gastrointestinal symptoms. *J Pediatr Gastroenterol Nutr* 2005; **41**: 305-316 [PMID: 16131985 DOI: 10.1097/01.mpg.0000172749.71726.13]
- 20 **Walker LS**, Lipani TA, Greene JW, Caines K, Stutts J, Polk DB, Caplan A, Rasquin-Weber A. Recurrent abdominal pain: symptom subtypes based on the Rome II Criteria for pediatric functional gastrointestinal disorders. *J Pediatr Gastroenterol Nutr* 2004; **38**: 187-191 [PMID: 14734882 DOI: 10.1097/00005176-200402000-00016]
- 21 **Schurman JV**, Friesen CA, Danda CE, Andre L, Welchert E, Lavenbarg T, Cocjin JT, Hyman PE. Diagnosing functional abdominal pain with the Rome II criteria: parent, child, and clinician agreement. *J Pediatr Gastroenterol Nutr* 2005; **41**: 291-295 [PMID: 16131983 DOI: 10.1097/01.mpg.0000178438.64675.e4]
- 22 **Uc A**, Hyman PE, Walker LS. Functional gastrointestinal disorders in African American children in primary care. *J Pediatr Gastroenterol Nutr* 2006; **42**: 270-274 [PMID: 16540795 DOI: 10.1097/01.mpg.0000189371.29911.68]
- 23 **Saps M**, Adams P, Bonilla S, Chogle A, Nichols-Vinueza D. Parental report of abdominal pain and abdominal pain-related functional gastrointestinal disorders from a community survey. *J Pediatr Gastroenterol Nutr* 2012; **55**: 707-710 [PMID: 22744191 DOI: 10.1097/MPG.0b013e3182662401]
- 24 **van Tilburg MA**, Squires M, Blois-Martin N, Leiby A, Langseder A. Test of the child/adolescent Rome III criteria: agreement with physician diagnosis and daily symptoms. *Neurogastroenterol Motil* 2013; **25**: 302-e246 [PMID: 23216900 DOI: 10.1111/nmo.12056]
- 25 **Lewis ML**, Palsson OS, Whitehead WE, van Tilburg MA. Prevalence of Functional Gastrointestinal Disorders in Children and Adolescents. *J Pediatr* 2016; **177**: 39-43.e3 [PMID: 27156185 DOI: 10.1016/j.jpeds.2016.04.008]
- 26 **Saps M**, Nichols-Vinueza DX, Rosen JM, Velasco-Benitez CA. Prevalence of functional gastrointestinal disorders in Colombian school children. *J Pediatr* 2014; **164**: 542-545.e1 [PMID: 24332822 DOI: 10.1016/j.jpeds.2013.10.088]
- 27 **Zablah R**, Velasco-Benitez CA, Merlos I, Bonilla S, Saps M. Prevalence of functional gastrointestinal disorders in school-aged children in El Salvador. *Rev Gastroenterol Mex* 2015; **80**: 186-191 [PMID: 26297182 DOI: 10.1016/j.rgmxen.2015.03.006]
- 28 **Lu PL**, Saps M, Chanis RA, Velasco-Benitez CA. The prevalence of functional gastrointestinal disorders in children in Panama: a school-based study. *Acta Paediatr* 2016; **105**: e232-e236 [PMID: 26933798 DOI: 10.1111/apa.13379]
- 29 **Lu PL**, Velasco-Benitez CA, Saps M. Gender, Age, and Prevalence of Pediatric Irritable Bowel Syndrome and Constipation in Colombia: A Population-Based Study. *J Pediatr Gastroenterol Nutr* 2016; Epub ahead of print [PMID: 27579696 DOI: 10.1097/MPG.0000000000001391]
- 30 **Játiva E**, Velasco-Benitez CA, Koppen IJ, Játiva-Cabezas Z,

- Saps M. Prevalence of Functional Gastrointestinal Disorders in Schoolchildren in Ecuador. *J Pediatr Gastroenterol Nutr* 2016; **63**: 25-28 [PMID: 26771768 DOI: 10.1097/MPG.0000000000001108]
- 31 **Burgers R**, Levin AD, Di Lorenzo C, Dijkgraaf MG, Benninga MA. Functional defecation disorders in children: comparing the Rome II with the Rome III criteria. *J Pediatr* 2012; **161**: 615-620. e1 [PMID: 22578584 DOI: 10.1016/j.jpeds.2012.03.060]
- 32 **Gijsbers CF**, Benninga MA, Schweizer JJ, Kneepkens CM, Vergouwe Y, Büller HA. Validation of the Rome III criteria and alarm symptoms for recurrent abdominal pain in children. *J Pediatr Gastroenterol Nutr* 2014; **58**: 779-785 [PMID: 24866784 DOI: 10.1097/MPG.0000000000000319]
- 33 **Cristofori F**, Fontana C, Magistà A, Capriati T, Indrio F, Castellana S, Cavallo L, Francavilla R. Increased prevalence of celiac disease among pediatric patients with irritable bowel syndrome: a 6-year prospective cohort study. *JAMA Pediatr* 2014; **168**: 555-560 [PMID: 24756157 DOI: 10.1001/jamapediatrics.2013.4984]
- 34 **Gulewitsch MD**, Enck P, Schwille-Kiuntke J, Weimer K, Schlarb AA. Rome III criteria in parents' hands: pain-related functional gastrointestinal disorders in community children and associations with somatic complaints and mental health. *Eur J Gastroenterol Hepatol* 2013; **25**: 1223-1229 [PMID: 24002016 DOI: 10.1097/MEG.0b013e328364b55d]
- 35 **Helgeland H**, Flagstad G, Grøtta J, Vandvik PO, Kristensen H, Markestad T. Diagnosing pediatric functional abdominal pain in children (4-15 years old) according to the Rome III Criteria: results from a Norwegian prospective study. *J Pediatr Gastroenterol Nutr* 2009; **49**: 309-315 [PMID: 19525874 DOI: 10.1097/MPG.0b013e31818de3ab]
- 36 **Devanarayana NM**, Adhikari C, Pannala W, Rajindrajith S. Prevalence of functional gastrointestinal diseases in a cohort of Sri Lankan adolescents: comparison between Rome II and Rome III criteria. *J Trop Pediatr* 2011; **57**: 34-39 [PMID: 20525779 DOI: 10.1093/tropej/fmq039]
- 37 **Dong L**, Dingguo L, Xiaoxing X, Hanming L. An epidemiologic study of irritable bowel syndrome in adolescents and children in China: a school-based study. *Pediatrics* 2005; **116**: e393-e396 [PMID: 16140684 DOI: 10.1542/peds.2004-2764]
- 38 **Zhou H**, Yao M, Cheng GY, Chen YP, Li DG. Prevalence and associated factors of functional gastrointestinal disorders and bowel habits in Chinese adolescents: a school-based study. *J Pediatr Gastroenterol Nutr* 2011; **53**: 168-173 [PMID: 21788758 DOI: 10.1097/MPG.0b013e3182125388]
- 39 **Rajindrajith S**, Devanarayana NM, Weerasooriya L, Hathagoda W, Benninga MA. Quality of life and somatic symptoms in children with constipation: a school-based study. *J Pediatr* 2013; **163**: 1069-1072. e1 [PMID: 23800401 DOI: 10.1016/j.jpeds.2013.05.012]
- 40 **Yamamoto R**, Kaneita Y, Osaki Y, Kanda H, Suzuki K, Higuchi S, Ikeda M, Kondo S, Munezawa T, Ohida T. Irritable bowel syndrome among Japanese adolescents: A nationally representative survey. *J Gastroenterol Hepatol* 2015; **30**: 1354-1360 [PMID: 25868086 DOI: 10.1111/jgh.12974]
- 41 **Udoh E**, Devanarayana NM, Rajindrajith S, Meremikwu M, Benninga MA. Abdominal Pain-predominant Functional Gastrointestinal Disorders in Adolescent Nigerians. *J Pediatr Gastroenterol Nutr* 2016; **62**: 588-593 [PMID: 26465793 DOI: 10.1097/MPG.0000000000000994]
- 42 **Vandenplas Y**, Abkari A, Bellaiche M, Benninga M, Chouraqui JP, Çokura F, Harb T, Hegar B, Lifschitz C, Ludwig T, Miqdady M, de Moraes MB, Osatakul S, Salvatore S, Shamir R, Staiano A, Szajewska H, Thapar N. Prevalence and Health Outcomes of Functional Gastrointestinal Symptoms in Infants From Birth to 12 Months of Age. *J Pediatr Gastroenterol Nutr* 2015; **61**: 531-537 [PMID: 26308317 DOI: 10.1097/MPG.0000000000000949]
- 43 **Ferreira-Maia AP**, Matijasevich A, Wang YP. Epidemiology of functional gastrointestinal disorders in infants and toddlers: A systematic review. *World J Gastroenterol* 2016; **22**: 6547-6558 [PMID: 27605889 DOI: 10.3748/wjg.v22.i28.6547]
- 44 **Schurman JV**, Hunter HL, Friesen CA. Conceptualization and treatment of chronic abdominal pain in pediatric gastroenterology practice. *J Pediatr Gastroenterol Nutr* 2010; **50**: 32-37 [PMID: 19915496 DOI: 10.1097/MPG.0b013e3181ae3610]

**P- Reviewer:** Contini S, Sun SY, Yucel O **S- Editor:** Ma YJ

**L- Editor:** Wang TQ **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045